Literature DB >> 10204906

Anxiety, vocalization, and agitation following peripheral nerve block with ropivacaine.

S M Klein1, H Benveniste.   

Abstract

BACKGROUND AND OBJECTIVES: Central nervous system (CNS) and cardiovascular toxicity are potential side effects of local anesthetics. However, ropivacaine has been reported to be less CNS toxic than bupivacaine in human volunteers.
METHODS: We describe three cases of peripheral nerve blockade with ropivacaine that resulted in unusual symptoms of CNS toxicity.
RESULTS: In three patients, unexpected behavioral changes occurred during administration of ropivacaine. The patients became extremely agitated, anxious, and screamed, and they did not respond to verbal commands.
CONCLUSION: This case report shows that ropivacaine may cause CNS toxicity that differs from classical signs of local anesthetic-induced toxicity. This effect might be related to the unique structure of ropivacaine, which is formulated in an S-enantiomer preparation. It has been shown that S-enantiomers bind differently to receptors in both the CNS and cardiovascular systems. This property may account for the disinhibition of select neural pathways that are specifically involved in mediation of anxiety and aggression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204906     DOI: 10.1016/s1098-7339(99)90081-0

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  3 in total

Review 1.  Anaesthetic agents for advanced regional anaesthesia: a North American perspective.

Authors:  Chester C Buckenmaier; Lisa L Bleckner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Ropivacaine: an update of its use in regional anaesthesia.

Authors:  K J McClellan; D Faulds
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

3.  [Successful infection control in regional anesthesia procedures: observational survey after introduction of the DGAI hygiene recommendations].

Authors:  F Reisig; M Neuburger; Y A Zausig; B M Graf; J Büttner
Journal:  Anaesthesist       Date:  2013-02-06       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.